CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple...

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) are distinct hematologic malignancies.
• The co-occurrence of MM and DLBCL in a single patient is exceptionally rare.
• Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 or B-cell maturation antigen (BCMA) show efficacy in hematologic cancers.

Observation:

• A patient presented with findings consistent with MM on bone marrow biopsy.
• A subsequent lymph node biopsy confirmed DLBCL.
• The patient had concurrent, distinct diagnoses of MM and DLBCL.

Findings:

• The patient received CD19-targeted CAR T-cell therapy.
• Post-treatment evaluation showed no detectable evidence of either MM or DLBCL.
• This represents the first reported case of concomitant MM and DLBCL treated with CD19-targeted CAR T-cell therapy.

Implications:

• CD19-targeted CAR T-cell therapy may be effective in treating patients with both MM and DLBCL.
• This case expands the understanding of CAR T-cell therapy applications in rare hematologic malignancy combinations.
• Further investigation is warranted to explore the efficacy of CAR T-cell therapy in similar rare co-occurring hematologic cancers.